A Phase 1 interventional study of Cannabis oil in Healthy, sponsored by GreenCare Pharma. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by GreenCare Pharma · Phase 1, Interventional, and Treatment
The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL. The main question it aims to answer is:
This is the only study on the registry with GreenCare Pharma as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Having participated in any experimental study or ingested any experimental drug within 1 (one) year prior to the start of this study;
Concentration unit: 79.14 mg/mL
Drug: Cannabis oil
Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages: Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg. Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days.
Also known as: Extrato de Cannabis sativa GreenCare 79.14 mg/mL
Identification of the Maximum Tolerated Dose (MTD) of Cannabis sativa Extract GreenCare 79,14 mg/mL
Time frame: Up to 5 days
Frequency, intensity, and severity of adverse events
Time frame: Up to 5 days
Plasma concentrations of CBD and THC
Time frame: Up to 5 days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.